4 August 2021
On 9 September, The Health Policy Partnership is holding an online event to launch the UK application of the Radioligand Therapy Readiness Assessment Framework. Join leading clinicians and experts from Prostate Cancer UK, Neuroendocrine Cancer UK and the British Nuclear Medicine Society for a detailed discussion on how to improve current integration and future readiness for radioligand therapy in the UK.
The materials developed as part of the framework application, including a Situation Analysis Report and accompanying Policy Action Blueprint, are the first documents of their kind. They provide an analysis of current integration of radioligand therapy in the UK and a set of policy recommendations to achieve health system readiness for the therapy.
This event will explore how to encourage multi-sectoral working to drive proactive policymaking for radioligand therapy. It will look at how the UK can build a ready system for integrating new targeted cancer therapies in the future.
The launch takes place from 14:00 to 15:30 BST on Thursday, 9 September and will be moderated by Dr Suzanne Wait of The Health Policy Partnership.
- Dr Martin Rolles, Radiotherapy Lead, Wales Cancer Network
- Dr John Buscombe, Former President, British Nuclear Medicine Society; Locum Consultant, Barts Health NHS Trust
- Ms Nikie Jervis, Patient Support Manager and Information Nurse Specialist, Neuroendocrine Cancer UK
- Ms Karen Stalbow, Head of Policy, Knowledge and Impact, Prostate Cancer UK
Plus more to be announced.
Radioligand therapy is a highly targeted cancer therapy which has the potential to improve and extend the lives of people with a variety of cancers. With new applications of radioligand therapy on the horizon, we must proactively plan for its wider use in future.